The efficacy of melatonin for sleep problems in children with autism, fragile X syndrome, or autism and fragile X syndrome.

Détails

ID Serval
serval:BIB_1174232CCC93
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Institution
Titre
The efficacy of melatonin for sleep problems in children with autism, fragile X syndrome, or autism and fragile X syndrome.
Périodique
Journal of Clinical Sleep Medicine
Auteur⸱e⸱s
Wirojanan J., Jacquemont S., Diaz R., Bacalman S., Anders T.F., Hagerman R.J., Goodlin-Jones B.L.
ISSN
1550-9389
Statut éditorial
Publié
Date de publication
2009
Volume
5
Numéro
2
Pages
145-150
Langue
anglais
Notes
Publication types: Journal Article ; Randomized Controlled Trial ; Research Support, N.I.H., Extramural ; Research Support, Non-U.S. Gov't Publication Status: ppublish
Résumé
STUDY OBJECTIVE: To determine the efficacy of melatonin on sleep problems in children with autistic spectrum disorder (ASD) and fragile X syndrome (FXS). METHODS: A 4-week, randomized, double blind, placebo-controlled, crossover design was conducted following a 1-week baseline period. Either melatonin, 3 mg, or placebo was given to participants for 2 weeks and then alternated for another 2 weeks. Sleep variables, including sleep duration, sleep-onset time, sleep-onset latency time, and the number of night awakenings, were recorded using an Actiwatch and from sleep diaries completed by parents. All participants had been thoroughly assessed for ASD and also had DNA testing for the diagnosis of FXS. RESULTS: Data were successfully obtained from the 12 of 18 subjects who completed the study (11 males, age range 2 to 15.25 years, mean 5.47, SD 3.6). Five participants met diagnostic criteria for ASD, 3 for FXS alone, 3 for FXS and ASD, and 1 for fragile X premutation. Eight out of 12 had melatonin first. The conclusions from a nonparametric repeated-measures technique indicate that mean night sleep duration was longer on melatonin than placebo by 21 minutes (p = .02), mean sleep-onset latency was shorter by 28 minutes (p = .0001), and mean sleep-onset time was earlier by 42 minutes (p = .02). CONCLUSION: The results of this study support the efficacy and tolerability of melatonin treatment for sleep problems in children with ASD and FXS.
Mots-clé
Adolescent, Autistic Disorder/complications, Central Nervous System Depressants/therapeutic use, Child, Child, Preschool, Cross-Over Studies, Double-Blind Method, Female, Fragile X Syndrome/complications, Humans, Male, Melatonin/therapeutic use, Sleep Disorders/complications, Sleep Disorders/drug therapy
Pubmed
Web of science
Création de la notice
09/02/2010 17:34
Dernière modification de la notice
20/08/2019 13:39
Données d'usage